A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This will be a Phase II, open label study to establish the effect of once-daily oral doses of
ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid
cancer in whom no standard therapeutic option is available.